<DOC>
	<DOCNO>NCT00378976</DOCNO>
	<brief_summary>Over 80 % HIV-1 infected person also seropositive HSV-2 . Increasingly , clinical epidemiologic evidence show role HSV increase HIV infectiousness . The evidence suggest HSV important cofactor HIV transmission . The trial 's purpose assess reduction HIV shed associate valacyclovir suppression HSV-2 reactivation . This proof-of-concept , randomize , double-blind , placebo control crossover trial 20 HIV/HSV-2 co-infected men , assessed effect daily valacyclovir HIV-1 level plasma rectal mucosa secretion .</brief_summary>
	<brief_title>HSV-2 Suppression Reduce HIV-1 Levels HIV-1 , HSV-2 Co-infected Men .</brief_title>
	<detailed_description>Herpes simplex virus type 2 ( HSV-2 ) common among HIV infect person . HSV-2 reactivation associate increase plasma genital HIV-1 level , vitro , HSV-2 upregulates HIV transcription . The trial assess whether HSV-2 suppression reduces rectal plasma HIV-1 level HIV-1 , HSV-2 co-infected men sex men ( MSM ) . Conducted Lima Peru , 20 antiretroviral naive HIV-1 HSV-2 seropositive MSM CD4 &gt; 200 randomly assign receive valacyclovir 500 mg bid placebo 8 week , 2 week washout period , follow alternative regimen 8 week . Men collect daily home anogenital swab HSV DNA PCR , three weekly anoscopy procedure collection rectal mucosal secretion HIV-1 RNA , HSV DNA , weekly plasma HIV-1 RNA PCR . Outcomes plasma rectal HIV-1 level study arm .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Greater 18 year old , Documented HIV1 seropositive , CD4 count great 200 , Not HIV antiretroviral therapy , HSV2 seropositive determined Focus EIA ( IN &gt; 3.5 ) Not intend move area duration study participation . Willing able : provide independent write informed consent ; undergo clinical evaluation ; take study drug direct ; adhere followup schedule . Bacterial STDs ( symptomatic STD syndrome laboratoryconfirmed asymptomatic gonorrhea syphilis ) treat within two week study enrollment random assignment . MSM meet follow criterion eligible study : Known history adverse reaction valacyclovir , acyclovir famciclovir ; Planned open label use acyclovir , valacyclovir , famciclovir Known medical history seizure Known renal failure , serum creatinine &gt; 2.0mg/dl Hematocrit &lt; 30 %</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HIV shed</keyword>
	<keyword>HSV suppression</keyword>
	<keyword>Co-infected</keyword>
	<keyword>MSM</keyword>
	<keyword>Reactivation</keyword>
	<keyword>Valacyclovir</keyword>
</DOC>